⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557540 | 1.00 | — | — | |
| SCHEMBL551922 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1426744 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL1500943 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL17386732 | 0.98 | — | — | |
| Coniine SCHEMBL13596004 | 0.93 | — | — | |
| Coniine SCHEMBL96923 | 0.93 | — | — | |
| Coniine SCHEMBL335908 | 0.93 | — | — | |
| Coniine SCHEMBL25731 | 0.91 | CYP2D6 (0.44) | — | |
| Coniine SCHEMBL25355 | 0.91 | CYP2D6 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091894-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-9814722-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110082133-A1 | PYRIDONE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2301922-A1 | PYRIDONE COMPOUND | Astellas Pharma Inc. (JP) | 2011-03-30 | — | — | EP | disclosed |